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UV Exposure Boosts Transcutaneous Immunization
and Improves Tumor Immunity: Cytotoxic T-Cell
Priming through the Skin
Pamela Stein1, Gerd Rechtsteiner1,4, Tobias Warger1,5, Tobias Bopp1, Thorsten Fuhr1, Steve Pru¨fer1,
Hans-Christian Probst1, Michael Stassen1, Peter Langguth2, Hansjo¨rg Schild1 and Markus P. Radsak1,3
Immunologic approaches to combat cancer aim at the induction of tumor-reactive immune responses to
achieve long-term protection. In this context, we recently developed a transcutaneous immunization (TCI)
method using the Toll-like receptor (TLR) 7 agonist imiquimod and a peptide epitope. Application onto intact
skin induces potent cytotoxic T lymphocyte (CTL) responses and protection against transplanted tumors. The
purpose of this study was to explore the effects of UV irradiation on imiquimod-based TCI. Here we show that
skin exposure to low-dose UV light before TCI with imiquimod strongly boosts specific CTL responses leading
to memory formation and enhanced tumor protection. Toward the mechanisms, we show that the activation
of bone-marrow-derived dermal dendritic cells (DCs), but not Langerin-expressing DCs, is responsible for
enhanced CTL activation. We describe an optimized TCI method that mediates enhanced CTL and antitumor
responses by a DC- and TLR-dependent mechanism. These data may provide the basis for the future
development of advanced vaccination protocols against tumors and persistent virus infections.
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INTRODUCTION
UV light may have a variety of acute and chronic effects on
the skin: acute exposure directly induces inflammatory
responses resulting in skin irritations or sunburn (Cooper
et al., 2003), whereas chronic or low-dose UV exposure
causes no apparent inflammatory reactions, but leads to
immunosuppression and the development of skin cancers
(Halliday and Lyons, 2008). UV-induced immunosuppression
is mediated by T regulatory (Treg) cells as clearly shown in
skin grafting models (Fisher and Kripke, 1982) and more
recently in delayed-type hypersensitivity (DTH) reactions
(Rana et al., 2008). In the latter models, IL-10-producing
CD4þCD25þFoxP3þ Treg cells have been identified to be
responsible for the diminished response against haptens
(Schwarz et al., 2004; Maeda et al., 2008).
In contrast, the imidazoquinoline derivative imiquimod is
a synthetic Toll-like receptor (TLR) 7 agonist (Hemmi et al.,
2002) and induces inflammatory responses when applied
to the skin (Palamara et al., 2004). Besides this, imiquimod is
also effective in patients with HPV-associated or malignant
skin diseases, when administered topically (Navi and
Huntley, 2004). In this context, we and others have shown
that the concurrent application of a cytotoxic T lymphocyte
(CTL) epitope with imiquimod onto the skin (transcutaneous
immunization, TCI) elicits potent primary CTL responses
(Thomsen et al., 2004; Rechtsteiner et al., 2005). Induction of
specific immune responses by TCI with imiquimod takes
advantage of the direct access to skin-resident antigen-
presenting cells (APC) to initiate adaptive immunity (Romani
et al., 1989; Stoitzner et al., 2008). However, TCI with
imiquimod alone merely mediates a delay in growth of
transplanted EG.7 tumors, as shown by us (Warger et al.,
2007) and also by others in B16 melanoma models (Itoh and
Celis, 2005; Stoitzner et al., 2008).
Thatcher et al. (2006) have investigated the concurrent use
of imiquimod with UV exposure. In a DTH model, they
showed that imiquimod treatment of the skin before UV
exposure prevents the establishment of UV-induced hapten
tolerance by an IL-12p70-dependent mechanism. Interest-
ingly, they found a synergistic activation of CD11cþ APC in
the draining lymph nodes on imiquimod and UV treatment.
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To evaluate whether this observation is relevant in the
context of transcutaneous vaccinations, we investigated
the effects of UV exposure on CTL responses induced by
TCI with imiquimod. We found that low-dose UV exposure
not only reverted UV-mediated suppression, but actually
boosted specific CTL responses leading to an enhanced
primary CTL response, efficient memory CTL formation
and improved tumor protection. Toward the mechanisms,
we show that UV/TCI with imiquimod is accompanied by an
increased recruitment of dermal CD11cþ dendritic cell
(dermal DC) to the draining lymph nodes. Taken together,
in this work we provide evidence that the combination of an
immunosuppressive with an immunostimulatory treatment of
the skin boosts a specific CTL response. These results may
provide the basis for advanced therapeutic vaccination
strategies against tumors and persistent infections.
RESULTS
UV strongly augments TCI with imiquimod-induced
primary CTL responses
UV light may be suppressive on local inflammation of the
skin (Maeda et al., 2008; Rana et al., 2008) and suppress
T cell-mediated immune responses (Ghoreishi and Dutz,
2006). This is prevented by the TLR7 agonist imiquimod
(Thatcher et al., 2006). To this end, we investigated the effects
of UV exposure in a DTH model in the presence or absence
of imiquimod. The mice were sensitized with dinitrofluor-
obenzene (DNFB) on the shaved back skin and challenged
4 days later on the ear. As depicted in Figure 1a and
consistent with others (Thatcher et al., 2006), local UV
exposure prevented ear swelling, whereas the response was
restored after the additional treatment with imiquimod. To
address directly how this kind of UV pretreatment affects
peptide-specific CTL responses elicited by TCI with imiqui-
mod, we applied imiquimod (50mg containing 2.5mg
imiquimod per day on 2 consecutive days) together with
the major histocompatibility complex (MHC) class I-restricted
T cell epitope OVA257–264 after low-dose UV-B exposure. We
detected a greatly increased frequency of peptide-specific
CD8 T cells after UV-B exposure compared with the robust
CTL activation detected after TCI with imiquimod alone
(Figure 1b). Notably, the combination of UV exposure with
imiquimod-based TCI not only restored, but greatly enhanced
T cell activation as indicated by an enormous increase in
cytolytic activity (Figure 1c).
To further characterize UV-enhanced TCI with imiqui-
mod, we pretreated the animals 24 hours before with UV light
of the A, B, or C spectra. The CTL response was analyzed
7 days later by the frequency of specific CTL and an in vivo
cytotoxicity assay. The pretreatment of the skin with UV-B
was superior to UV-C in the induction of specific CD8 T cells
(Supplementary Figure S1A online) with similar cytolytic
activity (Supplementary Figure S1B online). In contrast,
the pretreatment with UV-A did not increase the CTL
frequency or in vivo cytolytic activity compared with TCI
with imiquimod alone. These results indicated that precon-
ditioning of the skin with UV-B or C light enhances the TCI
with imiquimod-induced T cell response in a synergistic way.
UV-B-enhanced TCI with imiquimod induces improved
memory CTL formation
We have previously shown that TCI with imiquimod induces
a potent primary CTL response, but fails to induce significant
memory T cell formation due to inefficient co-stimulation.
This may be overcome by CD40 ligation (Warger et al.,
2007). As we found the most prominent primary CTL
response after TCI with imiquimod post-UV-B exposure, we
focused on UV-B-mediated effects in the following
experiments. We asked whether this treatment regimen also
has an impact on memory formation and analyzed the
peptide-specific CTL for frequency, phenotype and in vivo
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Figure 1. Modulation of T-cell responses in the skin by UV exposure and
imiquimod. (a) Mice were sensitized (0.5% dinitrofluorobenzene (DNFB))
after UV-B exposure (90mJ cm2) or imiquimod (2.5mg) as indicated.
Antigen challenge was performed 4 days later on the ears (0.2% DNFB).
(b, c) Mice were immunized by transcutaneous immunization (TCI) with
imiquimod (2.5mg) using the peptide SIINFEKL (100mg) in 50mg cream per
application without or after UV-B exposure (90mJ cm2). The frequency of
specific CD8þ T cells after 7 days in the spleen was assessed by flow
cytometry (b) or by in vivo cytolytic activity (c). A cumulative analysis of
four independent experiments, each performed with three mice per group,
is shown. *Significant difference to sens./chall., by unpaired Student’s t-test.
**Significant difference to UV-B by unpaired Student’s t-test.
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cytolytic activity over time, and in the memory phase after
immunization. The number of specific CD8 T cells decreased
over time after reaching a maximum after 1 week post-
immunization treatments (Figure 2a). After 40 days, peptide-
specific CTLs were detectable only in the group treated with
UV or CD40 ligation in addition to TCI with imiquimod. The
majority of these peptide-specific CTLs were antigen experi-
enced indicated by high expression of CD44 (anti-CD40/TCI:
95.4±2.1%; UV/TCI: 89.9±6.9%). Additional coexpression
of CD62Lhi compatible with a central memory phenotype
was found in: 34.7±13.9% in the anti-CD40/TCI group and
in 16.3±4.5% in the UV/TCI group, whereas the majority in
both groups had a CD44hiCD62Llo phenotype, consistent
with an effector phenotype (Seder and Ahmed, 2003).
Consistently, significant cytolytic activity was observed only
in these groups (Figure 2b).
These results suggest that the combination of low-dose
UV-B exposure with imiquimod-based TCI with imiquimod is
truly synergistic not only by inducing a superadditive primary
CTL response, but also by creating an effective memory
response as important prerequisite for long-term protective
immune responses. Importantly, the observed memory
response was almost comparable to TCI combined with
CD40 ligation that induces a functionally relevant memory
response as measured by long-term tumor protection (Warger
et al., 2007).
UV treatment synergizes with TCI with imiquimod in a
dose- and time-dependent manner
UV irradiation may induce skin irritation in a dose-dependent
manner. To determine the dose of UV-B required for the
synergistic effect on TCI with imiquimod, we treated mice
as before titrating the time of UV exposure from 30 to
300mJ cm2 one day before TCI with imiquimod. As measure
of skin irritation we determined the minimal erythema dose
after UV treatment, which was at 300mJ cm2 (Supplemen-
tary Figure S2 online) and consistent with others (Maeda
et al., 2008; Rana et al., 2008). There was a dose-dependent
enhancement of the TCI with imiquimod-induced CTL
response that was not further increased beyond 90mJ cm2
of UV-B (Figure 3a). Interestingly, the pretreatment with
UV light still augmented the induced CTL response at a UV
dose below the minimal erythema dose indicating that
the activation of skin-resident cells by UV treatment still
synergizes with TCI with imiquimod at a dosage below an
amount that causes visible irritation of the skin.
Next, we determined the time interval required between
UV and imiquimod treatment to induce the optimal CTL
response. Therefore, the interval between UV exposure and
TCI with imiquimod was varied to obtain the time sequence
for optimal CTL induction. We found the maximal CTL
response when UV treatment was performed 24 hours
before TCI with imiquimod, as observed by the frequency
of peptide-specific CD8þ T cells and target cell lysis
(Figure 3b and c). These results suggest that the activation
of skin-resident cells by UV irradiation sensitizes these cells
for TLR-mediated activation and enhanced peptide presenta-
tion to induce a superior CTL response within a narrow time
frame of 24–48 hours. Defining the spectra, timing, and dose
of UV exposure before TCI with imiquimod, we established a
treatment protocol resulting in a remarkably enhanced CTL
response without any additional skin irritation. Interestingly,
the optimal dose and timing of UV exposure before TCI with
imiquimod coincides with reported regimens for the genera-
tion of UV-induced tolerance (Fisher and Kripke, 1982;
Schwarz et al., 2004; Maeda et al., 2008; Rana et al., 2008).
UV/TCI with imiquimod increases protection against
EG.7 tumors
After characterizing an improved CTL induction upon TCI
with imiquimod post-UV-B exposure, we wanted to evaluate
this vaccination protocol in terms of tumor protection.
Therefore we inoculated EG.7 thymoma cells expressing
chicken ovalbumin as a surrogate tumor antigen. Tumors
were allowed to grow until palpable before the immunization
treatments were initiated: mice were either immunized
with TCI with imiquimod or with additional UV exposure at
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Figure 2. UV-B exposure before transcutaneous immunization (TCI) with
imiquimod induces a cytotoxic T lymphocyte (CTL) memory response.
(a) C57BL/6 mice were immunized by TCI with imiquimod in the absence
or presence of UV-B light (90mJ cm2) or after intravenous anti-CD40-Ab
(100mg) injection (days 3 to 0). The frequency of peptide-specific CD8þ
T cells was monitored after 7, 21, and 40 days. (b) After 30 days the in vivo
cytolytic activity was assessed after adoptive transfer of peptide loaded and
carboxyfluorescein diacetate succinimidyl ester-labeled target cells without
prior restimulation. The depicted results are summarized data from at least
three independent experiments with three mice per group. *Significant
difference by unpaired Student’s t-test.
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weekly intervals. UV exposure alone had no impact on
tumor growth compared with untreated animals (Figure 4a,
upper panel) and resulted in a median death after 22 days
(range 19–28). TCI with imiquimod significantly delayed
tumor growth and induced durable tumor regression in 8 of
37 mice (22%). Animals treated with UV exposure before TCI
with imiquimod all showed an initial response resulting in
significantly smaller tumors compared with the group without
UV treatment (Figure 4a, lower panel). Durable protection
was observed in 14 of 33 animals (42%) and significantly
higher compared with the group treated with TCI alone
(Figure 4b). Analysis of the relapsed tumors revealed that
tumor growth was not because of loss of the target antigen.
Reisolated tumor cells from tumor-bearing mice still
expressed the target epitope SIINFEKL in the context of H2-
Kb measured with a specific antibody (data not shown).
Together, these results indicate that the improved activation
of CTL induced by UV and TCI with imiquimod leads to
enhanced tumor protection.
Langerhans cells and dermal DC mediate CTL activation on
imiquimod-based TCI and UV/TCI
For the activation of CD8 T cells the interaction with
professional APC is crucial (Banchereau and Steinman,
1998). Using our imiquimod-based TCI approach, it was
found that T cells need to interact with skin-resident APC
such as Langerhans cells (LCs) or dermal DCs for priming
(Romani et al., 1989; Stoitzner et al., 2008). In this context, a
number of DC populations have been described besides
epidermal LCs: the CD11cþ dermal DC as well as bone-
marrow-derived Langerinþ dermal DC populations (Bennett
et al., 2005; Bursch et al., 2007; Ginhoux et al., 2007; Poulin
et al., 2007). To address the contributions of distinct DC
subsets, we analyzed the number and phenotype of DC
populations in the draining lymph nodes after imiquimod-
based TCI or UV/TCI and FITC treatment of the skin for the
identification of skin-derived DC populations. After the
immunization treatments, the number of skin-derived FITCþ
and CD11cþ DCs in the draining lymph nodes (Figure 5a),
but not Langerinþ DCs (Figure 5b), was increased with a
maximum after 2 days and additional UV exposure.
Furthermore, we found the increased induction of IL-12 in
the draining lymph nodes of the UV/TCI with imiquimod-
treated group compared with TCI with imiquimod alone or
the non-draining lymph nodes (Figure 5c). The majority of
FITCþ DCs were CD11cþCD11bþLangerin and had high
CD40 and CD86 expression (Figure 5d), compatible with an
activated dermal DC phenotype (Heath and Carbone, 2009).
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Figure 3. Low dose of UVB before transcutaneous immunization (TCI) with imiquimod leads to increased immune responses. C57BL/6 mice were immunized
and UV-B irradiated as indicated. (a) Dose of UV light was titrated from 0 to 300mJ cm2 and cytolytic activity was assessed. To determine the optimal timing
of UV treatment, we irradiated mice 48 or 24 hours before and 24 or 24þ 48hours after immunization. Specific CD8þ T cells (b) and cytolytic activity (c) were
quantified by flow cytometric analysis. One representative experiment out of two performed with n¼ 3 mice per group is shown. *A significant difference
(Po0.05) by unpaired Student’s t-test compared with the no-UV group in a or the 24 hour group in b and c.
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To address whether this CD11cþ DC population is relevant
for CTL priming on TCI with imiquimod, we took advantage
of mice transgenic for the diphtheria toxin receptor (DTR):
one mouse strain expressing the DTR specifically in LC under
the control of the Langerin promoter (Langerin-DTREGFP)
or another mouse strain expressing the DTR in CD11cþ DCs
(CD11c-DTR) under the control of the CD11c promoter. By
the administration of diphtheria toxin (DT) the respective DC
populations can be specifically ablated.
Langerin-DTREGFP mice were immunized as before
by imiquimod-based TCI with or without UV exposure. DT
treatment resulted in a near-total depletion of epidermal
Langerinþ cells as shown by immunohistology staining of
epidermal sheets (not shown). The CTL activity was reduced
to about 50% after imiquimod-based TCI with or without UV
exposure, indicating a significant contribution of these cells
to the induced CTL response (Figure 5d). To examine the
contribution of bone-marrow-derived Langerinþ or CD11cþ
DC subsets more closely, we generated chimeric mice in
which C57BL/6 wild-type mice were lethally irradiated and
reconstituted with bone marrow cells from Langerin-
DTREGFP or CD11c-DTR transgenic mice. In these animals,
radio-resistant LCs remain of host origin and not sensitive to
DT depletion whereas radio-sensitive dermal DC populations
are replaced by the transplanted DTR transgenic cells (Merad
et al., 2002; Ginhoux et al., 2007). Subsequently the chimeric
animals were treated with imiquimod-based TCI or UV/TCI
after depletion of the respective DC population. In this
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Figure 4. Delayed tumor growth and superior tumor protection after UV-B exposure before transcutaneous immunization (TCI). EG.7 cells (4105)
were injected subcutaneously into the flank of mice. Immunization treatments were started after 10–12 days after inoculation when tumors became palpable.
The mean tumor size with SEM (a) and survival (b) were monitored. Depicted are the cumulative results of four independent experiments with n¼ 37 mice
in the TCI group, n¼ 33 in the UV/TCI group, n¼33 in the UV group, and n¼ 30 mice in the untreated control group. *A significant difference (Po0.05)
between TCI and UV/TCI by Mantel–Cox test for survival analysis or by paired Student’s t-test for comparison of tumor growth; NS, not significant.
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situation, the depletion of bone-marrow-derived Langerinþ
cells did not lead to any alteration of the CTL responses
induced by either immunization protocol (Figure 5f), whereas
depletion of CD11cþ cells resulted in the complete abroga-
tion of the imiquimod-based TCI or UV/TCI-induced CTL
activity (Figure 5g). These data suggest that the CTL activation
on TCI with imiquimod is mediated primarily by bone-
marrow-derived dermal DCs and that epidermal LCs may
have an auxiliary role, but they are not essential for CTL
priming in this setting. Other DC populations such as bone-
marrow-derived Langerinþ DCs (Bursch et al., 2007)
obviously have no functional role in TCI with imiquimod-
induced CTL activation.
DISCUSSION
TCI might be an attractive way to deliver antigens for the
induction of curative immune responses against malignancies
or persistent virus infections by directly targeting skin-
resident APC. By combining the topical application of a
TLR agonist with a CTL epitope, potent primary T cell
responses are initiated (Rechtsteiner et al., 2005). However,
we and others experienced that TCI with imiquimod-induced
CTL responses rapidly fade away resulting in poor memory
formation and only partial tumor protection (Itoh and Celis,
2005; Warger et al., 2007; Stoitzner et al., 2008).
Because low-dose UV exposure has been shown to have a
synergistic effect on TLR7-mediated activation of APC
in vivo, we explored our imiquimod-based TCI protocol
toward UV-induced additional effects. A previous report
found no effect of UV exposure on cholera-toxin/tape-
stripping-based TCI with peptide (Ghoreishi and Dutz,
2006). However, we found that UV exposure before TCI
with imiquimod not only prevented UV-mediated tolerance
as suggested by previous results in a DTH model (Thatcher
et al., 2006), but actually boosted the peptide-specific CTL
response and also created a considerable memory response.
Toward the identification of the APC populations involved
and in line with a previous report (Thatcher et al., 2006), we
detected an increased number of CD11cþ , but not
Langerinþ , DCs in the draining lymph nodes on additional
FITC+CD11c+ DC FITC+Langerin+ cells
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UV after TCI with imiquimod. To address the functional
contribution this DC population to UV/TCI with imiquimod,
we used transgenic mice that can be specifically ablated of
distinct DC subsets and bone marrow chimeras of these to
evaluate their origin. Using this powerful technique we can
now attribute an important role for a dermal CD11cþ DC
population for CTL priming after TCI, especially after
additional UV exposure. We can exclude a significant
contribution of radio-sensitive, bone-marrow-derived
Langerinþ cells (Bursch et al., 2007; Ginhoux et al., 2007)
that seem important in cholera-toxin-based TCI (Chang et al.,
2008). The contribution of bone-marrow-derived CD11cþ
dermal DCs is well known and distinct from the role of LCs in
cross-priming and skin-associated immunity (Jung et al.,
2002; Kissenpfennig et al., 2005). However, the activation of
dermal DCs through TLR7 alone cannot explain the CTL
superactivation upon additional UV exposure. Thatcher et al.
(2006) show an increased production of IL12p70 of CD11cþ
DC on imiquimod/UVB treatment. Consistent with this
observation, we find an increased number of dermal DC
and the induction of IL-12 in the draining lymph nodes on
UV-B/imiquimod treatment. Therefore, we suggest that
imiquimod/UV treatment induces the improved activation
and migration of dermal DC to the regional lymph nodes
where this converts to superior CTL responses, possibly
mediated by IL-12. However, the exact molecular mechan-
isms how this superior DC activation is mediated remain to
be elucidated. The biologic and biochemical processes after
UV exposure are complex: potentially after UV exposure a
mediator is released that synergizes with the TLR7 ligands in
terms of DC activation, that is, urocanic acid (Walterscheid
et al., 2006). This might also occur indirectly with a role for
mast cells (Heib et al., 2007; Biggs et al., 2010) or Treg cells
that have a well-described role in UV-induced immunosup-
pression (Schwarz et al., 2004; Maeda et al., 2008). It might
be that Tregs directly or indirectly activated by UV become
functionally inactive in the presence of the inflammatory
milieu created by the TLR7 agonist and UV allowing an
improved CTL activation.
Taken together, we show the TLR agonist imiquimod can
turn UV-induced immunosuppression into a robust and long-
lasting CTL response. This enhanced CTL response is able to
reject established tumors expressing a target antigen. There-
fore future vaccination protocols may want to incorporate not
only activating adjuvants such as TLR agonist, but should also
include means to inhibit or modify immunosuppressive
factors. Our results provide some of the underlying mechan-
isms of TCI with imiquimod-based CTL responses and further
extend the basis for new TCI approaches to treat cancer or
persistent infections.
MATERIALS AND METHODS
Mice
C57BL/6 mice at 6–8 weeks were obtained from the local animal
facility of the University of Mainz. CD11c-DTR mice are on C57BL/6
background and were provided by S Jung (Jung et al., 2002).
Langerin-DTREGFP and Langerin-EGFP mice are on C57BL/6
background and were provided by B Malissen (Kissenpfennig
et al., 2005). All animal procedures were conducted in accordance
with the institutional guidelines.
DTH responses
C57BL/6 mice were sensitized by painting of DNFB (Sigma-Aldrich,
Taufkirchen, Germany) solution (50 ml; 0.5% in acetone/olive oil,
4:1) on the shaved back. After 4 days, 20 ml of 0.2% DNFB was
applied onto the left ear for elicitation. Ear swelling was quantified
with a caliper 24 hours after challenge. DTH was determined as the
amount of swelling of the hapten-challenged ear compared with the
thickness of the vehicle-treated ear and expressed in centimeters
 103 (mean±SD).
Transcutaneous immunizations
Transcutaneous immunizations with imiquimod were described
previously (Rechtsteiner et al., 2005). Briefly, dorsal hair was
removed with electric clippers. Peptides (100 mg in DMSO from
Sigma-Aldrich) were added to 50mg cream containing 5%
imiquimod (Aldara) or vehicle cream (both from 3M Pharmaceu-
ticals, St Paul, MN) and applied on the dorsal skin of anesthetized
mice on days 0 and 1. Synthetic peptide OVA257–264 (SIINFEKL) from
chicken ovalbumin was kindly provided by Dr Stevanovic (Depart-
ment Immunology, Institute for Cell Biology, University of Tu¨bingen,
Germany). Where indicated the anti-CD40 (clone FGK-45, a gift
from Dr R Offringa, Leiden, the Netherlands) antibody was
additionally applied by daily i.v. injection of 100mg antibody at
days 0, 1, and 2 (Warger et al., 2007).
UV exposure
In some experiments the animals were exposed to UV light at day 1
or as indicated. The shaved mice were anesthetized with ketamine/
xylazine (71.2:0.2mg per mouse) and placed under the respective
UV source at a distance of 25 cm from back skin. A narrow band UV
lamp (365 nm, 8W for UV-A; 312 nm, 8W for UV-B; 254 nm, 8W
for UV-C, all from Peqlab, Erlangen, Germany) was used. UV-B lamp
stably emitted light with 0.39mWcm2 measured with a UV
radiometer (UV34; PCE Group, Meschede, Germany). UVB doses
from 30 to 300mJ cm2 were calculated by the exposure times
ranging from 10 to 300 seconds with respect to the respective light
source.
Tumor rejection assay
Tumors were implanted by s.c. injection of 4 105 EG.7 thymoma
cells (from ATCC) as described previously (Warger et al., 2007).
Tumors were allowed to grow until palpable (10–12 days after
inoculation) before treatments were initiated. Tumor size was
monitored three times per week with a caliper measuring the diameter
in two dimensions. Mice were killed when tumor size exceeded
20mm in both diameters.
Flow cytometric analyses and in vivo cytotoxicity assay
The following mAbs were used for analyses by flow cytometry:
APC-Cy7-conjugated anti-CD8 (clone 53-6.7) and APC-conjugated
CD44 (clone IM7) (both from eBioscience, Frankfurt, Germany),
FITC-conjugated CD44 and PE-conjugated CD62L (clone MEL-14)
(from ImmunoTools, Friesoythe, Germany), and APC-conjugated
CD62L (from BD Pharmingen, Hamburg, Germany). Blood samples
were collected after tail vein incision and incubated on ice with
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specific mAbs as indicated after a hypotonic lysis step. H2-Kb-
SIINFEKL-specific T cells were detected by H2-Kb tetramer labeling
as described previously (Warger et al., 2006). The assessment of
in vivo cytolytic activity has been described (Rechtsteiner et al.,
2005). For the evaluation of the cytolytic activity in the memory
phase, target cells were transferred 30 days after immunization
without prior restimulation and splenocytes were analyzed by flow
cytometry 48 hours later. The expression of the target antigen on
EG.7 cells was assessed by flow cytometry labeling using a mAb
recognizing the OVA257–264 epitope in the context of H2-K
b (clone
25D1.16; Porgador et al., 1997). All analyses were performed with a
FACSCanto or a LSRII Flow Cytometer and FACSDiva software (BD
Pharmingen).
Preparation of lymph nodes
Langerin-EGFP transgenic mice or C57BL/6 mice after FITC painting
(400ml, 5mgml1 in acetone/dibutyl phthalate (1:1) with 5%
DMSO; all from Sigma-Aldrich) were used for these experiments
as indicated. After the specified treatments, cervical, axillar,
brachial, and inguinal lymph nodes were collected, picked,
and digested for 45minutes with type 2 collagenase (50 mgml1
from Worthington Biochemicals, Lakewood, NJ). The reaction was
stopped by adding 10mM EDTA (from Sigma-Aldrich). The cells
were labeled with the following mAbs: APC-Cy7-conjugated CD11c
(clone N418), PE-conjugated CD11b (clone M1/70) and CD8 (clone
53-6.7), PE-Cy7-conjugated CD205 (clone 205yekta), FITC-conju-
gated B220 (clone RA3-6B2), APC-conjugated CD86 (clone GL-1)
and CD40 (clone 1C10) (all from eBioscience); Pacific Blue MHC
class II (clone M5/114.15.2) and PE-Cy7-conjugated CD4 (clone
RM4-5) (both from BD Pharmingen). The cells were finally
resuspended in Trucount tubes (from BD Pharmingen) allowing the
absolute quantification according to the manufacturer’s instructions.
Detection of mRNA by qRT-PCR
mRNA was extracted from lymph node cells from draining or
nondraining lymph nodes 48 hours after the indicated immunization
treatments using Trizol (Invitrogen, Karlsruhe, Germany). cDNA was
synthesized with RevertAid M-MuLV reverse transcriptase according
to the manufacturer’s instructions (MBI Fermentas, St Leon-Rot,
Germany). Specific mRNA levels were quantified by RT–PCR using
the following oligonucleotide primers: IL-12p35 (forward) GTCAAT
CACGCTACCTCCTC; IL-12p35 (reverse) CTGCACAGCTCATCGAT
GGC; HGPRT (forward) GTTGGATACAGGCCAGACTTTGTTG; HG
PRT (reverse) GAGGGTAGGCTGGCCTATAGGCT. Oligonucleo-
tides were chosen to span at least one intron at the level of genomic
DNA. qRT-PCR analyses to quantify the expression of IL-12 and
murine HGPRT were performed in triplicates on an iCycler (Bio-Rad,
Munich, Germany) using the IQ SYBR Green Supermix (Bio-Rad).
After normalization of the data according to the expression
of HGPRT mRNA, the relative expression level IL-12 mRNA was
calculated.
Generation of bone marrow chimeras
Bone marrow chimeras were generated by lethal irradiation of
recipient C57BL/6 mice with 9.5Gy from Cs137 source (OB58-BA;
Buchler, Braunschweig, Germany) and i.v. transfer of 5 105 bone
marrow cells from the indicated donor strain. The animals were
maintained under specific pathogen-free conditions for 8 weeks
before use for the immunization experiments. Where indicated,
CD11cþ cells from bone marrow chimeras or Langerinþ cells from
Langerin-DTREGFP were depleted by i.p. injection of DT (300 ng;
Sigma-Aldrich). Chimeras were injected from day 3 to day 4 every
other day whereas Langerin-DTREGFP mice were injected at
day 2.
Statistical analysis
Different groups were analyzed by a two-tailed Student’s t-test or
Mann-Whitney U-test for comparison between two groups as
indicated. Survival analysis was performed by the Mantel–Cox test.
For all analyses, Po0.05 was considered statistically significant.
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